Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,908,456 papers from all fields of science
Search
Sign In
Create Free Account
CP 751871
Known as:
CP-751,871
, CP751,871
, CP-751871
Expand
A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. CP-751871…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
figitumumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Retraction. “Phase II study of the anti–insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or…
Journal of Clinical Oncology
2012
Corpus ID: 5931247
2012
2012
Preclinical Development Evaluation of the Antitumor Effects and Mechanisms of PF 00299804 , a Pan-HER Inhibitor , Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Hyun-Jin Nam
,
K. Ching
,
+7 authors
Y. Bang
2012
Corpus ID: 28866562
Recently, HER2-directed treatment, such as trastuzumab, has shown clinical benefit in HER2-amplified gastric cancer. On the basis…
Expand
2011
2011
Cancer Therapy : Preclinical The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of kras Mutation Status
Masanori
,
Hua Li
,
+7 authors
Y. Shinomura
2011
Corpus ID: 26646175
Purpose: Insulin-like growth factor (IGF)-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of…
Expand
2010
2010
Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies
D. Olmos
,
B. Basu
,
J. D. de Bono
Molecular Cancer Therapeutics
2010
Corpus ID: 20552
Activation of the insulin-like growth factor (IGF) pathway, by binding of the growth factors IGF-I and IGF-II to the receptors…
Expand
2010
2010
Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors.
R. Quek
,
J. Morgan
,
+7 authors
S. George
2010
Corpus ID: 78380286
10002 Background: Preclinical models demonstrate synergistic antitumor activity with combination blockade of mTOR and IGF-IR…
Expand
2010
2010
Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).
E. Calvo
,
W. Ma
,
+7 authors
A. Adjei
2010
Corpus ID: 79391760
3026 Background: Cross-talk between human epidermal growth factor receptor (HER) and insulin-like growth factor type I receptor…
Expand
2010
2010
Abstract 3488: In vitro activity of the IGF-1R inhibitor CP-751,871, as a single agent and in combination with paclitaxel, in lung and colon cell lines
M. T. Agulló-Ortuño
,
C. V. Díaz-García
,
+6 authors
L. Paz-Ares
2010
Corpus ID: 72610399
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Background: Signaling through the insulin-like…
Expand
2008
2008
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2008
Corpus ID: 38287257
(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC…
Expand
Review
2007
Review
2007
Phase IDose Escalation Study of theAnti ^ Insulin-Like Growth Factor-IReceptor Monoclonal Antibody CP-751 , 871 in Patients with Refractory SolidTumors
P. Haluska
,
H. Shaw
,
+9 authors
A. Bono
2007
Corpus ID: 30271285
Purpose:This phase I study was undertaken to define the maximum tolerated dose, safety, and pharmacokinetic profile of CP-751,871…
Expand
2007
2007
Advanced NSCLC: CP‐751871 IGF‐1R Antibody as First‐Line Therapy Produces High Response Rates
R. Carlson
2007
Corpus ID: 87150007